206 related articles for article (PubMed ID: 22404985)
21. Milatuzumab - a promising new immunotherapeutic agent.
Berkova Z; Tao RH; Samaniego F
Expert Opin Investig Drugs; 2010 Jan; 19(1):141-9. PubMed ID: 19968579
[TBL] [Abstract][Full Text] [Related]
22. Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single particle image analysis.
Karakikes I; Morrison IE; O'Toole P; Metodieva G; Navarrete CV; Gomez J; Miranda-Sayago JM; Cherry RJ; Metodiev M; Fernandez N
FASEB J; 2012 Dec; 26(12):4886-96. PubMed ID: 22889831
[TBL] [Abstract][Full Text] [Related]
23. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
Hertlein E; Triantafillou G; Sass EJ; Hessler JD; Zhang X; Jarjoura D; Lucas DM; Muthusamy N; Goldenberg DM; Lee RJ; Byrd JC
Blood; 2010 Oct; 116(14):2554-8. PubMed ID: 20574049
[TBL] [Abstract][Full Text] [Related]
24. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
25. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.
Zheng YX; Yang M; Rong TT; Yuan XL; Ma YH; Wang ZH; Shen LS; Cui L
World J Gastroenterol; 2012 May; 18(18):2253-61. PubMed ID: 22611320
[TBL] [Abstract][Full Text] [Related]
26. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
27. A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance.
Vandenbark AA; Meza-Romero R; Benedek G; Andrew S; Huan J; Chou YK; Buenafe AC; Dahan R; Reiter Y; Mooney JL; Offner H; Burrows GG
J Autoimmun; 2013 Feb; 40():96-110. PubMed ID: 23026773
[TBL] [Abstract][Full Text] [Related]
28. Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).
Wallace DJ; Figueras F; Wegener WA; Goldenberg DM
Ann Rheum Dis; 2021 Jul; 80(7):954-955. PubMed ID: 33619162
[No Abstract] [Full Text] [Related]
29. CD74: a new candidate target for the immunotherapy of B-cell neoplasms.
Stein R; Mattes MJ; Cardillo TM; Hansen HJ; Chang CH; Burton J; Govindan S; Goldenberg DM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5556s-5563s. PubMed ID: 17875789
[TBL] [Abstract][Full Text] [Related]
30. Splenectomy of rats selectively reduces lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1 expression on B-cell subsets in blood and lymph nodes.
Milićević NM; Luettig B; Trautwein C; Wüstefeld T; Mähler M; Jecker P; Wonigeit K; Westermann J
Blood; 2001 Nov; 98(10):3035-41. PubMed ID: 11698288
[TBL] [Abstract][Full Text] [Related]
31. Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas.
Cuthbert RJ; Wilson JM; Scott N; Coletta PL; Hull MA
Eur J Cancer; 2009 Jun; 45(9):1654-63. PubMed ID: 19269807
[TBL] [Abstract][Full Text] [Related]
32. Activation of CD74 inhibits migration of human mesenchymal stem cells.
Barrilleaux BL; Fischer-Valuck BW; Gilliam JK; Phinney DG; O'Connor KC
In Vitro Cell Dev Biol Anim; 2010 Jun; 46(6):566-72. PubMed ID: 20198449
[TBL] [Abstract][Full Text] [Related]
33. The D-6 mouse monoclonal antibody recognizes the CD74 cytoplasmic tail.
Genève L; Gauthier C; Thibodeau J
Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):221-7. PubMed ID: 25171001
[TBL] [Abstract][Full Text] [Related]
34. MIF inhibits monocytic movement through a non-canonical receptor and disruption of temporal Rho GTPase activities in U-937 cells.
DiCosmo-Ponticello CJ; Hoover D; Coffman FD; Cohen S; Cohen MC
Cytokine; 2014 Sep; 69(1):47-55. PubMed ID: 25022961
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.
Thavayogarajah T; Sinitski D; El Bounkari O; Torres-Garcia L; Lewinsky H; Harjung A; Chen HR; Panse J; Vankann L; Shachar I; Bernhagen J; Koschmieder S
Exp Hematol; 2022 Nov; 115():30-43. PubMed ID: 36096455
[TBL] [Abstract][Full Text] [Related]
36. Both host and parasite MIF molecules bind to chicken macrophages via CD74 surface receptor.
Kim S; Cox CM; Jenkins MC; Fetterer RH; Miska KB; Dalloul RA
Dev Comp Immunol; 2014 Dec; 47(2):319-26. PubMed ID: 25086294
[TBL] [Abstract][Full Text] [Related]
37. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.
Wilson KM; Labeta MO; Pawelec G; Fernandez N
Immunology; 1993 Jun; 79(2):331-5. PubMed ID: 8344710
[TBL] [Abstract][Full Text] [Related]
38. CD74 expression and its therapeutic potential in thyroid carcinoma.
Cheng SP; Liu CL; Chen MJ; Chien MN; Leung CH; Lin CH; Hsu YC; Lee JJ
Endocr Relat Cancer; 2015 Apr; 22(2):179-90. PubMed ID: 25600560
[TBL] [Abstract][Full Text] [Related]
39. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.
Giltiay NV; Shu GL; Shock A; Clark EA
Arthritis Res Ther; 2017 May; 19(1):91. PubMed ID: 28506291
[TBL] [Abstract][Full Text] [Related]
40. N-Octanoyl-Dopamine inhibits cytokine production in activated T-cells and diminishes MHC-class-II expression as well as adhesion molecules in IFNγ-stimulated endothelial cells.
Hofmann BB; Krapp N; Li Y; De La Torre C; Sol M; Braun JD; Kolibabka M; Pallavi P; Krämer BK; Yard BA; Kälsch AI
Sci Rep; 2019 Dec; 9(1):19338. PubMed ID: 31853095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
